alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities, J Neurochem, vol.150, pp.522-534, 2019. ,
URL : https://hal.archives-ouvertes.fr/cea-02279218
Chaperone-mediated autophagy markers in Parkinson disease brains, Arch Neurol, vol.67, pp.1464-72, 2010. ,
Phosphorylation of Ser-129 is the dominant pathological modification of alphasynuclein in familial and sporadic Lewy body disease, J Biol Chem, vol.281, pp.29739-52, 2006. ,
Mechanisms underlying extensive Ser129-phosphorylation in alpha-synuclein aggregates, Acta Neuropathol Commun, vol.5, p.48, 2017. ,
Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA, Acta Neuropathol Commun, vol.2, p.29, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01183383
Structural and functional characterization of two alpha-synuclein strains, Nat Commun, vol.4, p.2575, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01183047
Fighting neurodegeneration with rapamycin: mechanistic insights, Nat Rev Neurosci, vol.12, pp.437-52, 2011. ,
Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis, J Neurochem, vol.110, pp.1005-1018, 2009. ,
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy, Science, vol.305, pp.1292-1297, 2004. ,
Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated alpha-Synuclein-selective Autophagic Degradation, All rights reserved DAHMENE, vol.292, pp.3919-3928, 2017. ,
Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome, Neurobiol Aging, vol.31, pp.953-68, 2010. ,
Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins, Acta Neuropathol, vol.134, pp.629-653, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01571238
alpha-Synuclein is phosphorylated in synucleinopathy lesions, Nat Cell Biol, vol.4, pp.160-164, 2002. ,
Autophagy activation promotes clearance of alpha-synuclein inclusions in fibril-seeded human neural cells, J Biol Chem, vol.294, pp.14241-14256, 2019. ,
The Synucleinopathies: Twenty Years On, J Parkinsons Dis, vol.7, pp.51-69, 2017. ,
Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards non-toxic parallel beta-sheet structured species, Sci Rep, vol.7, p.41755, 2017. ,
Palpha-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria, Neurobiol Dis, vol.124, pp.248-262, 2019. ,
Propagation of alpha-Synuclein Strains within Human Reconstructed Neuronal Network, Stem Cell Reports, vol.12, pp.230-244, 2019. ,
Accepted Article This article is protected by copyright. All rights reserved Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice, Sci Rep, vol.7, p.16533, 2017. ,
,
Selective imaging of internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies, J Biol Chem, vol.292, pp.13482-13497, 2017. ,
Proteasomal inhibition by alpha-synuclein filaments and oligomers, J Biol Chem, vol.279, pp.12924-12958, 2004. ,
Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, vol.338, pp.949-53, 2012. ,
Exogenous alpha-synuclein fibrils seed the formation of Lewy bodylike intracellular inclusions in cultured cells, Proc Natl Acad Sci U S A, vol.106, pp.20051-20057, 2009. ,
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner, J Biol Chem, vol.285, pp.40732-40776, 2010. ,
The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology, Front Mol Neurosci, vol.10, p.311, 2017. ,
Prion-like spreading of pathological alphasynuclein in brain, Brain, vol.136, pp.1128-1166, 2013. ,
alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models, Proc Natl Acad Sci U S A, vol.113, pp.1931-1937, 2016. ,
Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases, J Parkinsons Dis, vol.5, pp.217-244, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01155416
Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker, J Neurosci, vol.34, pp.12368-78, 2014. ,
Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice, Proc Natl Acad Sci U S A, vol.111, pp.10732-10739, 2014. ,
, , 2014.
, Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice, Acta Neuropathol, vol.127, pp.645-65
Proteolysis of alpha-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology, J Neurochem, vol.140, pp.662-678, 2017. ,
Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions, J Biol Chem, vol.289, pp.31224-31264, 2014. ,
How is alpha-synuclein cleared from the cell?, J Neurochem, vol.150, pp.577-590, 2019. ,
, LC3 and Autophagy, vol.445, pp.77-88, 2008.
Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy, J Biol Chem, vol.288, pp.15194-210, 2013. ,
, , 2010.
, Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice, Acta Neuropathol, vol.120, pp.145-54
Phosphorylation modulates clearance of alphasynuclein inclusions in a yeast model of Parkinson's disease, PLoS Genet, vol.10, p.1004302, 2014. ,
A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders, J Biomol Struct Dyn, vol.21, pp.211-245, 2003. ,
Pathological roles of alpha-synuclein in neurological disorders, Lancet Neurol, vol.10, pp.1015-1040, 2011. ,
Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent nonapoptotic death, J Neurochem, vol.109, pp.1348-62, 2009. ,
Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells, J Biol Chem, vol.283, pp.23542-56, 2008. ,
,
Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes, Mol Biol Cell, vol.25, pp.4010-4033, 2014. ,
Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron, vol.72, pp.57-71, 2011. ,
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein, J Neuropathol Exp Neurol, vol.67, pp.402-418, 2008. ,
A novel, high-efficiency cellular model of fibrillar alphasynuclein inclusions and the examination of mutations that inhibit amyloid formation, J Neurochem, vol.113, pp.374-88, 2010. ,
Alpha-Synuclein is degraded by both autophagy and the proteasome, 25009-immunocytochemistry with anti-?-Syn (pS129) and anti-Tuj1 antibodies. Expression of pS129 ?, vol.278, 2003. ,
, untreated or treated with epoxomicin for 24 hours, were assessed for SDSsoluble pS129 ?-Syn. F. Cells were harvested and subjected to fractionated western immunoblotting (Tx-100 and SDS soluble fraction) with anti-pS129, anti-cjun, and anti-?-tubulin antibodies. G, H. Quantification of SDS-soluble phosphorylated ?-Syn levels (monomeric species) in d7 (G) and 7d-/2d+ (H) cells. For quantification (B, G and H), data are presented as the mean ± SD of 3 independent cell preparations; one-way ANOVA with Bonferonni's correction was used for (B) and student's t-test for (G) and (H). I. 7 days after high-dose PFF (400ng/ml) addition, -and +DOX cells, non-treated, epoxomicin-or bafilomycin-treated, were lysed, fractionated and subjected to PK treatment, followed by western immunoblotting with anti-pS129, anti-p62, anti-LC3 and anti-?-tubulin antibodies. Representative blot from 3 independent cell preparations. J,K. -, + DOX and 7d-/2d+ cells (without or with high-dose PFFs-400ng/ml), in the absence or presence of pharmacological reagents (bafilomycin, epoxomicin) were lysed at indicated time points (day 7, day 9) with a nuclear-sparing buffer, Syn (red) and Tuj1 (green) was observed using fluorescence confocal microscopy. Scale bar 30 ?m. E. 7 and 9 days after high-dose PFF (400ng/ml) addition, differentiated SH-SY5Y cells (-or +DOX and 7d-/2d+)
, SH-SY5Y differentiated cells with inducible expression of ?-Syn can serve as a model to investigate aggregation propensity and clearance of PFFtriggered ?-Syn assemblies. PFFs are internalized within 48h (1) and 6 days post-PFF, endogenous ?-Syn is seeded and detected mostly around the nucleus (2), Figure 7. Schematic illustration of the SH-SY5Y inducible neuronal model, fine-tuned for investigating aggregated ?-Syn turnover